Q3 2025 · 13F-HR
Flagship Pioneering, LLCholdings as filed
Filed 2025-11-14 · accession 0001193125-25-282859
$292.6M
Reported value
4
Positions
2025-09-30
Period end
The Brief · Flagship Pioneering, LLC · Q3 2025
AI · grounded in 13F
Flagship Pioneering, LLC established a new position in Moderna Inc MRNA valued at $119.6M. The fund also added new holdings in Sana Biotechnology Inc SANA and Foghorn Therapeutics Inc FHTX, worth $88.8M and $62M respectively. A final new position was opened in Seres Therapeutics Inc MCRB for $22.2M. Total assets under management for the fund stand at $292.6M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 60770K107 | MRNA | Moderna Inc | $119.6M | 40.9% | 4,632,149 | Common | SHARED |
| 799566104 | SANA | Sana Biotechnology Inc | $88.8M | 30.3% | 25,001,856 | Common | SHARED |
| 344174107 | FHTX | Foghorn Therapeutics Inc | $62.0M | 21.2% | 12,674,120 | Common | SHARED |
| 81750R201 | MCRB | Seres Therapeutics Inc | $22.2M | 7.60% | 1,155,850 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.